About CLOP

This startup develops an AI-powered platform for early detection of diabetic retinopathy by analyzing retinal images. Their technology helps prevent vision loss by identifying the condition in its initial stages, enabling timely intervention.

```xml <problem> Diabetic retinopathy, a major complication of diabetes, often leads to blindness if not detected and treated early. Despite the availability of screening methods, fewer than 20% of diabetic patients receive regular retinal examinations, resulting in delayed diagnosis and potential vision loss. The lack of efficient referral systems between primary care physicians and ophthalmologists further exacerbates this issue. </problem> <solution> CLOP Inc. offers an AI-powered platform, "Afternoon," designed to facilitate early detection and timely management of diabetic retinopathy. The platform streamlines the referral process by connecting primary care physicians with local ophthalmologists, ensuring that patients at risk receive prompt eye examinations. By integrating AI-driven image analysis, the platform assists in identifying early signs of diabetic retinopathy, enabling timely intervention and treatment. This comprehensive approach aims to increase screening rates among diabetic patients, promote proactive eye health management, and ultimately reduce the incidence of preventable blindness. </solution> <features> - AI-powered analysis of retinal images for early detection of diabetic retinopathy - Referral platform connecting primary care physicians and ophthalmologists - Facilitates efficient communication and collaboration between medical professionals - Provides a streamlined system for scheduling and managing patient referrals - Supports early diagnosis and timely treatment of diabetic retinopathy - Contributes to the prevention of vision loss among diabetic patients - Integrates with existing healthcare systems for seamless data exchange </features> <target_audience> The primary target audience includes primary care physicians, ophthalmologists, and diabetic patients seeking proactive management of diabetic retinopathy. </target_audience> ```

What does CLOP do?

Where is CLOP located?

CLOP is based in 성남시, 대한민국.

When was CLOP founded?

CLOP was founded in 2023.

Who founded CLOP?

CLOP was founded by Sang Jun Park.

Sang Jun Park - Founder and Co-CEO, Professor of SNUBH, Ophthalmologist (Retina Specialist)

Location

성남시, 대한민국

Founded

2023

Employees

9 employees

Looking for specific startups?

Try our free semantic startup search

CLOP

Score: 36/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

clop.ai 10+

Founded 2023 – 성남시, 대한민국

Funding

No funding information available. Click "Fetch funding" to run a targeted funding scan.

Team (5+)

Sang Jun Park

Founder and Co-CEO, Professor of SNUBH, Ophthalmologist (Retina Specialist)

Company Description

Problem

Diabetic retinopathy, a major complication of diabetes, often leads to blindness if not detected and treated early. Despite the availability of screening methods, fewer than 20% of diabetic patients receive regular retinal examinations, resulting in delayed diagnosis and potential vision loss. The lack of efficient referral systems between primary care physicians and ophthalmologists further exacerbates this issue.

Solution

CLOP Inc. offers an AI-powered platform, "Afternoon," designed to facilitate early detection and timely management of diabetic retinopathy. The platform streamlines the referral process by connecting primary care physicians with local ophthalmologists, ensuring that patients at risk receive prompt eye examinations. By integrating AI-driven image analysis, the platform assists in identifying early signs of diabetic retinopathy, enabling timely intervention and treatment. This comprehensive approach aims to increase screening rates among diabetic patients, promote proactive eye health management, and ultimately reduce the incidence of preventable blindness.

Features

AI-powered analysis of retinal images for early detection of diabetic retinopathy

Referral platform connecting primary care physicians and ophthalmologists

Facilitates efficient communication and collaboration between medical professionals

Provides a streamlined system for scheduling and managing patient referrals

Supports early diagnosis and timely treatment of diabetic retinopathy

Contributes to the prevention of vision loss among diabetic patients

Integrates with existing healthcare systems for seamless data exchange

Target Audience

The primary target audience includes primary care physicians, ophthalmologists, and diabetic patients seeking proactive management of diabetic retinopathy.